ClinicalTrials.gg
Sign In
RecruitingNCT03233399Updated Sep 25, 2026

Modulating Movement Intention Via Cortical Stimulation

An interventional study of Sham TMS3 stimulation and rTMS of left or right angular gyrus (AG) or frontal cortex (FC) in Seizures, Seizure Disorder and Psychogenic Movement Disorder, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Jul 2017; still recruiting 9 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.

Read the detailed description

This study will:

  • Explore effects of TMS and tDCS on movement intention.
  • Discern the neural activity underlying modulation of movement intention with neuroimaging recording.
  • Identify brain stimulation's effect in patients with psychogenic tremor and non-epileptic seizures.
  • Technical development of new experimental paradigms and data analysis methods.
  • Data collection for hypotheses development.
02

Conditions studied

  • Seizures
  • Seizure Disorder
  • Psychogenic Movement Disorder

Keywords

  • Electroencephalography
  • Magnetoencephalography
  • Transcranial Magnetic Stimulation
03

In context

Seizures

766 studies on the registry are indexed under Seizures; 136 are open to participants now.

This study's planned enrollment of 30 is below the median of 64 across 519 interventional studies indexed under Seizures.

Browse Seizures studies →

Lead sponsor

NYU Langone Health is the lead sponsor of 1,430 studies on the registry; 258 are open to participants now.

Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.

Browse NYU Langone Health studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(Healthy Controls)

  • Fluent in English

(Patients with PMD or PNES):

  • Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders.
  • Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening

Exclusion criteria

Exclusion Criteria:

  • Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI
  • Chronic or progressive medical condition
  • Any history of traumatic brain injury or significant head trauma
  • Currently meets criteria for substance abuse or dependence
  • History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation
  • Pregnancy
  • Metal or devices in the head, including neurostimulators or metal foreign bodies
  • Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.
  • Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).
  • Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009
  • Current diagnosis of any inflammatory or disorder within last 6 months

PMD and PNES Patients

  • Any history of traumatic brain injury or significant head trauma
  • Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures;
  • Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s);
  • Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months
  • Metal or devices in the head, including neurostimulators or metal foreign bodies
  • Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009;
  • Diagnosis of dementia, or (MoCA) ≤24;
  • Recurrent visual hallucinations, within the past 6 months;
  • History of significant uncontrollable movements of the head;
  • Any abnormality on vital signs
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Healthy Patients

    All healthy volunteers will complete the healthy volunteer form, MRI safety screening form, and the Montreal Cognitive Assessment (MOCA).

    Device: Sham TMS3 stimulation · Device: rTMS of left or right angular gyrus (AG) or frontal cortex (FC) · Device: Anodal tDCS of left or right AG or FC

  • Active comparator
    PMD/PNES patients

    PMD and PNES subjects will be referred by the treating

    Device: Sham TMS3 stimulation · Device: rTMS of left or right angular gyrus (AG) or frontal cortex (FC) · Device: Anodal tDCS of left or right AG or FC

Interventions

  • DeviceSham TMS3 stimulation

    half of the subjects will receive sham stimulation first

  • DevicerTMS of left or right angular gyrus (AG) or frontal cortex (FC)

    Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.

    Also known as: 45 Minutes

  • DeviceAnodal tDCS of left or right AG or FC

    Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.

    Also known as: 30 Minutes

06

What researchers measure

Primary outcomes

  1. Changes in signal intensity measured using of tDCS

    as a result of altering cerebral perfusion in response to neurophysiologic stimulation

    Time frame: 30 Minutes

  2. Changes in signal intensity measured during EEG recording

    as a result of altering cerebral perfusion in response to neurophysiologic stimulation

    Time frame: 3 Hours

  3. Changes in signal intensity measured during MEG

    as a result of altering cerebral perfusion in response to neurophysiologic stimulation

    Time frame: 3 Hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for May 2027, 118 months after the start.

Of 74 non-industry interventional studies with no phase under Seizures, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 118 months is above that.

Counting every sponsor, half of 83 studies reached it within 32 months; a quarter within 22 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2017
First posted
Jul 28, 2017
StartActual
Jul 20, 2017
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and contact details
1 update, last Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Minor edits only
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03233399
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jul 28, 2017
Start date
Jul 20, 2017
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Nalini Jeet
Contact
Nalini.Jeet@nyulangone.org
(212) 263-0228
Biyu He, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Seizures →

Other studies from this sponsor

NYU Langone Health →

Start the discussion